Universität zu Köln

Bergmark, Brian A., O'Donoghue, Michelle L., Murphy, Sabina A., Kuder, Julia F., Ezhov, Marat V., Ceska, Richard, Gouni-Berthold, Ioanna, Jensen, Henrik K., Tokgozoglu, S. Lale, Mach, Francois, Huber, Kurt, Gaciong, Zbigniew, Lewis, Basil S., Schiele, Francois, Jukema, J. Wouter, Pedersen, Terje R., Giugliano, Robert P. and Sabatine, Marc S. (2020). An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiol., 5 (6). S. 709 - 714. CHICAGO: AMER MEDICAL ASSOC. ISSN 2380-6591

Giugliano, Robert P., Pedersen, Terje R., Park, Jeong-Gun, De Ferrari, Gaetano M., Gaciong, Zbigniew A., Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose ORCID: 0000-0002-8844-0718, Schiele, Francois, Mach, Francois, Ott, Brian R., Kanevsky, Estelle, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M., Keech, Anthony C., Sever, Peter S. and Sabatine, Marc S. (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 390 (10106). S. 1962 - 1972. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

O'Donoghue, Michelle L., Fazio, Sergio, Giugliano, Robert P., Stroes, Erik S. G., Kanevsky, Estella, Gouni-Berthold, Ioanna, Im, KyungAh, Pineda, Armando Lira, Wasserman, Scott M., Ceska, Richard, Ezhov, Marat V., Jukema, J. Wouter, Jensen, Henrik K., Tokgozoglu, S. Lale, Mach, Francois, Huber, Kurt, Sever, Peter S., Keech, Anthony C., Pedersen, Terje R. and Sabatine, Marc S. (2019). Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. Circulation, 139 (12). S. 1483 - 1493. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1524-4539

Sabatine, Marc S., Leiter, Lawrence A., Wiviott, Stephen D., Giugliano, Robert P., Deedwania, Prakash, De Ferrari, Gaetano M., Murphy, Sabina A., Kuder, Julia F., Gouni-Berthold, Ioanna, Lewis, Basil S., Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C., Sever, Peter S. and Pedersen, Terje R. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol., 5 (12). S. 941 - 951. NEW YORK: ELSEVIER SCIENCE INC. ISSN 2213-8587

Sever, Peter, Gouni-Berthold, Ioanna, Keech, Anthony, Giugliano, Robert, Pedersen, Terje R., Im, KyungAh, Wang, Huei, Knusel, Beat, Sabatine, Marc S. and O'Donoghue, Michelle L. . LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur. J. Prev. Cardiol.. LONDON: SAGE PUBLICATIONS LTD. ISSN 2047-4881